Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. VIC activation on TCPS.
  • Fig. S2. Materials characterization of PEG hydrogels.
  • Fig. S3. VIC activation on soft hydrogels in healthy human serum.
  • Fig. S4. Individual factors identified in pre-TAVR serum mediate myofibroblast activation.
  • Fig. S5. Inhibition of p38 MAPK in VICs cultured on TCPS.
  • Fig. S6. Myofibroblast deactivation on TCPS.
  • Fig. S7. VIC activation on soft and stiff hydrogels.
  • Fig. S8. ARVF activation in control FBS and healthy human serum on soft and stiff hydrogels.
  • Fig. S9. Correlation between ARVF and VIC deactivation fold changes on soft hydrogels.
  • Fig. S10. Validation of post-TAVR serum factors mediating VIC deactivation on stiff hydrogels.
  • Fig. S11. Serum from male and female patients with AVS is altered after a TAVR procedure.
  • Legends for tables S1 to S9
  • Legend for data file S2
  • Reference (73)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 contains the following supplementary tables:
  • Table S1 (Microsoft Excel format). Patient information.
  • Table S2 (Microsoft Excel format). SOMAscan proteomic results.
  • Table S3 (Microsoft Excel format). GO analysis for pre-TAVR serum factors.
  • Table S4 (Microsoft Excel format). GO analysis for post-TAVR serum factors.
  • Table S5 (Microsoft Excel format). Transcriptomics results for VICs treated with pre-TAVR versus post-TAVR serum.
  • Table S6 (Microsoft Excel format). KEGG enrichment for up-regulated genes in pre-TAVR samples.
  • Table S7 (Microsoft Excel format). KEGG enrichment for down-regulated genes in pre-TAVR samples.
  • Table S8 (Microsoft Excel format). Sex-specific analysis of proteomic data.
  • Table S9 (Microsoft Excel format). Sex-specific analysis of transcriptomic data.
  • Data file S2 (Microsoft Excel format). Individual subject-level raw values for all experiments.